Jon R. Moeller, Executive Chairman of Procter & Gamble (PG), has demonstrated a clear selling bias in his recent insider transactions, with no open-market purchases recorded in the latest filings. His activity spans two companies—primarily PG, with a smaller holding in Eli Lilly (LLY)—but all recent monetization events involve PG shares. Between February 11 and 12, 2026, Moeller executed four sales totaling $47.8 million, including a single $26.4 million transaction on February 12. These disposals follow earlier sales in 2025, including a $6.3 million transaction in August and a $1.8 million sale in October. The only non-sale activity in late 2025 involved the acquisition of LLY shares via award transactions valued at $238,333, though no subsequent sales of this position appear in the data.
Moeller’s trading history shows $36.5 million in total sell-side value against $20.1 million in buys, with all purchases occurring in earlier periods. The recent acceleration of sales—particularly the two high-value February 2026 transactions—suggests a focus on liquidating PG holdings. The absence of any buys since at least mid-2025, combined with the concentration of sales in PG stock, indicates a directional reduction in exposure to his primary company. Transaction codes reveal that most sales were discretionary (code "S"), with smaller amounts tied to mandatory tax-related events (code "M"). The pattern aligns with an executive unwinding a long-held position rather than periodic rebalancing.
AI-assisted summary